Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 770371 Alone or With Ezabenlimab in Advanced Solid Tumours
NCT05327946Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- May 2022
- Primary completion
- Jul 2024
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
- Countries
- 3
01
Overview
Phase 1, open-label trial of BI 770371 in solid tumor (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Dose Limiting Toxicities in monotherapy at 21 days and Dose Limiting Toxicities in combination therapy at 21 days. Started May 2022; status: active, not recruiting.
02
Drugs
BI 770371
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05327946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05327946.